RxDoctor Payments Data

Donald Stewart, MD

Ophthalmology · Charlotte, NCNPI 1225093578

Payments from drug & device makers

$1,178in general payments, 2019–2025

Across 40 payments — averaging $29.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$662
  • Alcon$172
  • Astellas Pharma US Inc$123
  • AstraZeneca$100
  • AbbVie$67
  • Novartis$22
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$1,07892%
  • Education$1008%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)30$662
Alcon2$172
Astellas Pharma US Inc1$123
AstraZeneca1$100
AbbVie(2 entities)3$67
Novartis1$22
Bausch & Lomb Americas Inc.1$20
ANI Pharmaceuticals, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,178 in reported general payments places this provider in the 40th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$361,461
Medicare patients
1,405
Services billed
14,674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine35$47,289
LumiganBimatoprost36$19,263
CombiganBrimonidine Tartrate/Timolol35$14,852
Cyclosporine11$9,817
Brimonidine Tartrate67$6,526
Latanoprost333$3,852
Alphagan PBrimonidine Tartrate13$3,579
Timolol Maleate267$3,492
Pyridostigmine Bromide32$1,977
Prednisolone Acetate35$1,024
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha89$985
MoxifloxacinMoxifloxacin Hcl29$931
Dorzolamide Hcl47$703
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat37$670
Ketorolac Tromethamine12$322

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$67$84,984119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 588 ophthalmology providers in North Carolina.

Other ophthalmology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →